Published in Hepatology on March 01, 2005
Mammalian Krüppel-like factors in health and diseases. Physiol Rev (2010) 4.09
Expression and Function of Kruppel Like-Factors (KLF) in Carcinogenesis. Curr Genomics (2009) 1.01
Functional role of the KLF6 tumour suppressor gene in gastric cancer. Eur J Cancer (2008) 0.85
Aberrant expression of krUppel-like factor 6 protein in colorectal cancers. World J Gastroenterol (2006) 0.84
Nuclear expression of KLF6 tumor suppressor factor is highly associated with overexpression of ERBB2 oncoprotein in ductal breast carcinomas. PLoS One (2010) 0.83
Inactivation of the tumor suppressor Krüppel-like factor 6 (KLF6) by mutation or decreased expression in hepatocellular carcinomas. J Zhejiang Univ Sci B (2006) 0.81
Krüppel-like factor 6 expression changes during trophoblast syncytialization and transactivates ßhCG and PSG placental genes. PLoS One (2011) 0.77
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
The life history of 21 breast cancers. Cell (2012) 10.59
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 6.65
Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology (2006) 5.46
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature (2008) 5.38
MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology (2008) 5.28
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73
Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology (2014) 3.31
Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology (2007) 3.18
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun (2013) 3.06
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00
Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet (2002) 2.85
Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology (2014) 2.68
A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology (2013) 2.37
Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology (2009) 2.20
Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med (2011) 2.03
Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology (2013) 1.85
Genetics of hepatobiliary carcinogenesis. Semin Liver Dis (2011) 1.79
Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int J Biochem Cell Biol (2005) 1.79
Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat Genet (2007) 1.68
Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol (2007) 1.65
Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. Am J Clin Pathol (2012) 1.65
Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology (2008) 1.58
Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology (2005) 1.52
Expression of the transcription factor Klf6 in cirrhosis, macronodules, and hepatocellular carcinoma. J Gastroenterol Hepatol (2008) 1.48
Hepatocellular adenomas. Liver Int (2008) 1.47
Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. J Clin Endocrinol Metab (2004) 1.46
Benign and malignant vascular tumors of the liver in adults. Semin Liver Dis (2008) 1.39
Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology (2013) 1.36
HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J Biol Chem (2007) 1.36
Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers. Semin Liver Dis (2011) 1.35
Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34
Subtype classification of hepatocellular adenoma. Dig Surg (2010) 1.33
CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells. Eur J Cancer (2011) 1.26
Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. J Hepatol (2012) 1.25
GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol (2011) 1.25
Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. Gastroenterology (2003) 1.22
Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. Hum Mol Genet (2005) 1.22
Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin Liver Dis (2010) 1.21
Genotype phenotype classification of hepatocellular adenoma. World J Gastroenterol (2007) 1.21
Evaluation of liver tumors using acoustic radiation force impulse elastography and correlation with histologic data. J Ultrasound Med (2013) 1.21
Prognostic factors and longterm survival after hepatic resection for hepatocellular carcinoma originating from noncirrhotic liver. J Am Coll Surg (2005) 1.18
Over-expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver Int (2008) 1.17
Loss of hepatocyte nuclear factor 1alpha function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis. Hepatology (2010) 1.15
Proteomic analysis of differentially expressed proteins in hepatocellular carcinoma developed in patients with chronic viral hepatitis C. Proteomics (2005) 1.14
Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation. Hepatology (2011) 1.14
Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage. Diabetes (2010) 1.13
Hepatocellular adenoma: what is new in 2008. Hepatol Int (2008) 1.12
Overexpression and role of the ATPase and putative DNA helicase RuvB-like 2 in human hepatocellular carcinoma. Hepatology (2007) 1.08
The HOX gene network in hepatocellular carcinoma. Int J Cancer (2011) 1.07
The beta-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules. J Hepatol (2008) 1.06
Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. J Hepatol (2012) 1.05
Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. J Hepatol (2004) 1.04
Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res (2010) 1.04
STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica (2013) 1.04
Cellular retinol-binding protein-1 expression in normal and fibrotic/cirrhotic human liver: different patterns of expression in hepatic stellate cells and (myo)fibroblast subpopulations. J Hepatol (2004) 1.03
Markers for microvascular invasion in hepatocellular carcinoma: where do we stand? Liver Transpl (2011) 1.02
PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer (2013) 1.02
A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J Natl Cancer Inst (2010) 1.02
Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers. Clin Cancer Res (2010) 1.01
Adenosine triphosphatase pontin is overexpressed in hepatocellular carcinoma and coregulated with reptin through a new posttranslational mechanism. Hepatology (2009) 1.00
Sorafenib-mediated targeting of the AAA⁺ ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death. Mol Cancer Ther (2012) 1.00
Fibrogenic cell fate during fibrotic tissue remodelling observed in rat and human cultured liver slices. J Hepatol (2006) 1.00
Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1alpha-mutated hepatocellular adenoma. Cancer Res (2007) 0.99
Mosaicism for oncogenic G12D KRAS mutation associated with epidermal nevus, polycystic kidneys and rhabdomyosarcoma. J Med Genet (2010) 0.99